Avelas Biosciences Selected as a 2019 Showcase Company by MedTech Innovator
June 17, 2019
SAN DIEGO, June 27, 2019 – Avelas Biosciences, Inc., a clinical-stage oncology company developing AVB-620 for real-time cancer detection, has been selected as a 2019 Showcase company by MedTech Innovator. MedTech Innovator’s flagship four-month program provides best-in-class medical device, diagnostic, and digital health companies unparalleled visibility and access to leading manufacturers, providers, investors, and other industry stakeholders.
“We are thrilled and honored to announce Avelas’ selection to the MedTech Innovator 2019 Showcase program,” said Jay Lichter, Chief Executive Officer of Avelas. “The Showcase program is a prestigious opportunity to access key stakeholders across the medtech industry, including potential investors and partners. More importantly, it is a recognition of the burden that women who have to undergo a second breast cancer surgery face and how AVB-620 could positively impact the lives of hundreds of thousands of women each year.”
The program begins on June 19, 2019, in San Francisco with a two-day event leading up to the Wilson Sonsini Goodrich & Rosati’s 27th Annual Medical Device Conference on June 21, at which Avelas will present and participate in partnering. The program culminates Sept. 23-25, 2019, in Boston, where Avelas will present in a Showcase panel and participate in partnering at The MedTech Conference powered by AdvaMed.
Since 2013, MedTech Innovator has reviewed more than 3,000 startups and graduated 185 companies that have gone on to raise more than $1B in follow-on funding and bring 37 products to the market. MedTech Innovator works closely with stakeholders across the industry to foster the growth of early to mid-stage startups. In collaboration with 20 corporate partners, as well as a broader network of hundreds of investors, business development representatives, and industry experts, MedTech Innovator provides startups with individualized mentorship and feedback, funding opportunities, and continual engagement with peers and advisors.
For more information about MedTech Innovator and the Showcase program, please visit https://medtechinnovator.org/.
About Avelas Biosciences
Avelas Biosciences is a San Diego-based drug-device company focused on developing AVB-620, a novel drug-device combination product for use during cancer surgery. AVB-620 improves surgery by detecting cancer in real-time and has the potential to become part of standard-of-care treatment for a variety of cancer surgeries. AVB-620 has completed a Phase Ib clinical trial assessing safety, pharmacokinetics, and fluorescence properties using tissue image analysis. A Phase II clinical trial for AVB-620 in breast cancer is ongoing. Avelas was founded on technology from Roger Y. Tsien, Ph.D., co-winner of the 2008 Nobel Prize in chemistry.
About MedTech Innovator
Based in Los Angeles, Calif., MedTech Innovator is the premier nonprofit startup accelerator in the medical technology industry. Its mission is to improve the lives of patients by accelerating the growth of companies that are transforming the healthcare system. MedTech Innovator matches healthcare industry leaders with innovative early-stage and emerging growth medtech companies for mentorship and support.